Recruiting

OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)

ClinicalTrials.gov IDNCT06462963

PhaseNA

Enrollment302

SponsorEuropean Organisation for Research and Treatment of Cancer - EORTC

AgeNo minimum reported

SexALL

I'm interested View official listing

Conditions studied

Breast Cancer, Prostate Cancer, NSCLC, Colorectal Cancer, Oligometastatic Disease

About this study

The goal of this clinical trial is to evaluate single-fraction metastases-directed SBRT in the broader radiation oncology community and to compare its safety and efficacy profile with the current Standard of Care (SoC) of multiple-fraction SBRT in patients with oligometastatic disease of primary breast, prostate, NSCLC and colorectal cancer having all lesions that will be treated with radical radiotherapy amenable to single-fraction SBRT. The main question/hypothesis this clinical trial aims to answer is: \- Single-fraction SBRT has comparable outcomes as those obtained with multiple fraction SBRT, both in terms of safety and efficacy. Patients from the OligoCare cohort will be randomized to receive either single-fraction SBRT or the current SoC of multiple-fraction SBRT.

Interventions

Radiation: single-fraction SBRT — Single-fraction SBRT (Stereotactic Body Radiation Therapy) is a precise form of radiation therapy that delivers a high dose of radiation in a single treatment session to a targeted area, often used for treating small, well-defined tumors. This approach minimizes exposure to surrounding healthy tissues while effectively treating the tumor.
Radiation: multiple-fraction SBRT — Multiple-fraction SBRT (Stereotactic Body Radiation Therapy) is a precise form of radiation therapy that delivers high doses of radiation over several treatment sessions to a targeted area, typically used for treating small, well-defined tumors. This method helps to further protect surrounding healthy tissues by spreading the total radiation dose over multiple sessions.

Primary outcomes

Grade 3+ SBRT-related toxicity (within 12 months following treatment with radical radiotherapy.)

Eligibility information

Inclusion Criteria: * Patient is part of the RP1822-OligoCare. As in OligoCare, ALL active cancer lesions (loco-regional primary and all oligometastases) were or will be treated with radical intent (surgery or radiotherapy). * All lesions that will be treated with radical radiotherapy have to be amenable to single-fraction SBRT. Concurrent systemic treatment is allowed. * Written informed consent must be given according to ICH/GCP, and national/local regulations. Patients will be consented in a step-wise approach. Step 1 \[both control and experimental arms\]: patients will need to consent to be included and evaluated in E²-RADIatE (that includes the non-interventional OligoCare prospective registry cohort) and to potentially be randomized to future sub-studies for which they are eligible; no further consent will be sought if they are randomized to the SoC (control) arm; Step 2 \[experimental arm only\]: if eligible for the current sub-study and randomized to receive single-fraction SBRT, patients will need to consent to receiving the experimental treatment. Exclusion Criteria: All targeted lesion judged by the treating physician to be associated with risks for severe toxicity following single-fraction SBRT. The following lesions are systematically excluded: * Pulmonary metastases within 1 cm of proximal bronchial tree, esophagus or brachial plexus * Metastases within \< 5 mm of any hollow GI structure: esophagus, stomach, small bowel, large bowel * Metastases within \< 5 mm of the spinal cord, the cauda equina or the brachial plexus * Metastases \> 5 cm in largest diameter.

Study locations

Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium
Institut Jules Bordet, Brussels, Belgium
Universitair Ziekenhuis Gent, Ghent, Belgium
AZ Groeninge Kortrijk, Kortrijk, Belgium
Ziekenhuis aan de Stroom (ZAS) - ZAS Augustinus, Wilrijk, Belgium
Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
Istituto Clinico Humanitas, Milan, Italy
Istituto Europeo di Oncologia, Milan, Italy
Sacro Cuore Hospital, Negrar, Italy
Policlinico Universitario Campus Bio-Medico- Oncology Center, Roma, Italy

Showing 10 of 15 reported sites. See the official listing for all locations.

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.